CGEM

Cullinan is a pre-revenue, clinical-stage T-cell-engager biotech whose investment case rests entirely on pipeline readouts, not financials. The income statement is exactly what you'd expect of a Phase 1 shop: no product revenue since the FY2021 collaboration ($18.9M) lapsed, a FY2025 net loss of -$220M (widening 31% YoY) and operating loss of -$242M, with R&D up 31% to $187M as the OUTRACE autoimmune program scales. ROE of -53.8% is meaningless here except as a measure of burn against equity. What keeps this off the 'avoid' pile is the balance sheet: $387M current assets against just $39.6M total liabilities (liabilities/equity 0.10x) and $409M equity — a clean, near-debt-free book. The MD&A's $176M operating cash burn against that liquidity implies roughly two years of runway, so a dilutive raise (shares already +3.4% YoY) is a when-not-if, but not an imminent solvency threat.

The reason to hold rather than dismiss is an unusually dense, near-term catalyst calendar. CLN-978, a CD19xCD3 bispecific, sits in the market's hottest theme — B-cell-depleting T-cell engagers in autoimmune disease — with initial SLE/RA data due Q2 2026 (effectively now), RA repeat-dosing in Q3 and Sjögren's in Q4. Optionality is layered on top: partner Taiho completed a rolling NDA submission for zipalertinib in EGFR ex20ins NSCLC in February 2026 (accelerated-approval path) with REZILIENT3 Phase 3 topline expected by year-end, plus CLN-049 in AML heading toward a pivotal design. A ~$1.1B market cap (60.5M shares at $18.42) against ~$0.39B of liquid assets is not cheap, but it is not absurd for a partnered late-stage asset plus a credible autoimmune shot-on-goal.